present in ~40% of PV patients Plethora (facial redness/ruddy complexion) due to increased RBC mass and skin hyperemia Headache, dizziness, and visual disturbances from hyperviscosity and reduced cerebral blood flow Splenomegaly palpable in 7090% of PV patients from extramedullary hematopoiesis Thrombotic events (DVT, stroke, MI, Budd-Chiari syndrome) major complications from hyperviscosity Erythromelalgia burning pain/redness of hands and feet due to platelet-mediated microvascular occlusion Gout from elevated uric acid due to increased cell turnover Hypertension common comorbidity in PV Bleeding tendency paradoxically, despite elevated platelets, qualitative platelet dysfunction can cause GI bleeding Signs and symptoms that are routinely associated with a confirmed diagnosis of anemia or polycythemia (e.g., tachycardia, fatigue, pallor with anemia
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH), while Ipamorelin is a selective growth hormone secretagogue meaning it stimulates the pituitary to release growth hormone with fewer off-target effects than older compounds
Light protection: Keep the vial in its original box or a small opaque container
Patients with fibromyalgia and chronic pain often experience lasting relief, improved mobility, and increased energy levels with regenerative treatments
Without writing a book and explaining every single trial in detail, Ill share the key takeaway points: Trials #1-4 demonstrated an excellent safety profile in which AOD-9604 was well-tolerated and safe, with next to no difference compared to a placebo Trial #5 saw patients taking the AOD-9604 peptide lose 2.8 kg on a dose of 1 mg, compared to the placebo group losing 0.8 kg over the same time period
